5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial. (nature.com)

Authors: Perez-Garcia JM … Llombart-Cussac A Journal: Nature Medicine Published: 2026-10-29 DOI: https://doi.org/10.1038/s41591-026-04723-w